Tower Research Capital (TRC)’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $266K | Sell |
3,001
-5,789
| -66% | -$422K | 0.01% | 1480 |
|
|
2026
Q1 | $443K | Buy |
8,790
+8,365
| +1,968% | +$315K | 0.01% | 993 |
|
|
2025
Q4 | $13.9K | Sell |
425
-4,171
| -91% | -$109K | ﹤0.01% | 3384 |
|
|
2025
Q3 | $77K | Sell |
4,596
-1,173
| -20% | -$19.1K | ﹤0.01% | 2200 |
|
|
2025
Q2 | $86.4K | Buy |
5,769
+3,725
| +182% | +$55.1K | ﹤0.01% | 2502 |
|
|
2025
Q1 | $33K | Sell |
2,044
-6,530
| -76% | -$136K | ﹤0.01% | 2547 |
|
|
2024
Q4 | $200K | Buy |
8,574
+8,054
| +1,549% | +$236K | ﹤0.01% | 1717 |
|
|
2024
Q3 | $15.3K | Sell |
520
-2,864
| -85% | -$79.8K | ﹤0.01% | 3415 |
|
|
2024
Q2 | $79.6K | Sell |
3,384
-444
| -12% | -$15K | ﹤0.01% | 2753 |
|
|
2024
Q1 | $145K | Buy |
3,828
+1,248
| +48% | +$36.2K | ﹤0.01% | 1618 |
|
|
2023
Q4 | $55.5K | Buy |
2,580
+2,158
| +511% | +$29.7K | ﹤0.01% | 3060 |
|
|
2023
Q3 | $5.17K | Sell |
422
-488
| -54% | -$6.45K | ﹤0.01% | 4752 |
|
|
2023
Q2 | $10.3K | Sell |
910
-585
| -39% | -$2.77K | ﹤0.01% | 4143 |
|
|
2023
Q1 | $11K | Buy |
1,495
+781
| +109% | +$8.57K | ﹤0.01% | 4267 |
|
|
2022
Q4 | $8K | Sell |
714
-361
| -34% | -$6.49K | ﹤0.01% | 4455 |
|
|
2022
Q3 | $14K | Buy |
1,075
+447
| +71% | +$5.52K | ﹤0.01% | 4228 |
|
|
2022
Q2 | $8K | Sell |
628
-255
| -29% | -$8.94K | ﹤0.01% | 4711 |
|
|
2022
Q1 | $51K | Buy |
883
+685
| +346% | +$57.5K | ﹤0.01% | 2716 |
|
|
2021
Q4 | $24K | Buy |
198
+68
| +52% | +$10.7K | ﹤0.01% | 3478 |
|
|
2021
Q3 | $26K | Buy |
130
+9
| +7% | +$1.57K | ﹤0.01% | 3489 |
|
|
2021
Q2 | $21K | Buy |
121
+15
| +14% | +$2.73K | ﹤0.01% | 3855 |
|
|
2021
Q1 | $21K | Sell |
106
-234
| -69% | -$44.9K | ﹤0.01% | 3848 |
|
|
2020
Q4 | $67K | Sell |
340
-1,091
| -76% | -$226K | ﹤0.01% | 2788 |
|
|
2020
Q3 | $254K | Buy |
1,431
+1,007
| +238% | +$186K | ﹤0.01% | 2337 |
|
|
2020
Q2 | $98K | Buy |
+424
| New | +$80.8K | ﹤0.01% | 2480 |
|
|
2020
Q1 | – | Sell |
-292
| Closed | -$56K | – | 3859 |
|
|
2019
Q4 | $56K | Buy |
292
+235
| +412% | +$46.1K | ﹤0.01% | 1272 |
|
|
2019
Q3 | $11K | Buy |
+57
| New | +$11.1K | ﹤0.01% | 2884 |
|
|
2019
Q1 | – | Sell |
-93
| Closed | -$17K | – | 4262 |
|
|
2018
Q4 | $17K | Buy |
93
+87
| +1,450% | +$18.5K | ﹤0.01% | 2069 |
|
|
2018
Q3 | $1K | Buy |
+6
| New | +$1.4K | ﹤0.01% | 3627 |
|
|
2017
Q3 | – | Sell |
-9
| Closed | -$1K | – | 4130 |
|
|
2017
Q2 | $1K | Buy |
+9
| New | +$1.24K | ﹤0.01% | 2519 |
|
|
2017
Q1 | – | Sell |
-8
| Closed | -$1K | – | 3880 |
|
|
2016
Q4 | $1K | Sell |
8
-20
| -71% | -$2.92K | ﹤0.01% | 3661 |
|
|
2016
Q3 | $5K | Sell |
28
-3
| -10% | -$417 | ﹤0.01% | 2576 |
|
|
2016
Q2 | $4K | Buy |
+31
| New | +$5.94K | ﹤0.01% | 3559 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
Tower Research Capital (TRC)'s SYRE Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Spyre Therapeutics (SYRE) stake by 66% in Q2 2026, selling an estimated $422K and leaving 3,001 shares worth $266K. The position accounts for 0.01% of the portfolio, ranked #1480.
Tower Research Capital (TRC) first reported a position in SYRE in Q2 2016 and has held it in 33 quarters since. The position peaked at $443K in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- Tower Research Capital (TRC) held 3,001 shares of Spyre Therapeutics worth $266K as of Q2 2026.
- Tower Research Capital (TRC) sold 5,789 Spyre Therapeutics shares in Q2 2026, an estimated $422K.
- Spyre Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1480 holding.
- Tower Research Capital (TRC) first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 33 quarters since.
- Tower Research Capital (TRC)'s Spyre Therapeutics position peaked at $443K in Q1 2026.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.